Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

PMID:
18387931
2.

Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.

Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE.

JAMA. 2013 Sep 18;310(11):1135-44. doi: 10.1001/jama.2013.277169.

PMID:
23999933
3.

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE.

JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951.

PMID:
27846344
4.

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.

JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252.

PMID:
16478899
5.

Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.

O'Leary DH, Reuwer AQ, Nissen SE, Després JP, Deanfield JE, Brown MW, Zhou R, Zabbatino SM, Job B, Kastelein JJ, Visseren FL; AUDITOR investigators.

Heart. 2011 Jul;97(14):1143-50. doi: 10.1136/hrt.2011.223446. Epub 2011 May 24.

PMID:
21610270
6.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators.

JAMA. 2006 Apr 5;295(13):1556-65. Epub 2006 Mar 13.

PMID:
16533939
7.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators.

JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.

PMID:
18378631
8.

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

Hollander P.

Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32.

PMID:
17296341
9.

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370.

10.

STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.

[No authors listed]

Cardiovasc J Afr. 2008 May-Jun;19(3):158-9. No abstract available.

11.

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.

Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258.

12.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Christopoulou FD, Kiortsis DN.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. Review.

PMID:
21198716
13.

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17;353(20):2121-34.

14.
15.

Rimonabant and progression of atherosclerosis in obese persons.

Dora JM, Scheffel RS.

JAMA. 2008 Jul 16;300(3):280; author reply 280-1. doi: 10.1001/jama.2008.24. No abstract available.

PMID:
18632538
16.

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. doi: 10.1161/ATVBAHA.108.176362. Epub 2008 Dec 26.

17.

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.

Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y; CIRRUS Study Group.

Addiction. 2009 Feb;104(2):266-76. doi: 10.1111/j.1360-0443.2008.02454.x.

PMID:
19149823
18.

Does rimonabant independently affect free fatty acid and glucose metabolism?

Triay J, Mundi M, Klein S, Toledo FG, Smith SR, Abu-Lebdeh H, Jensen M.

J Clin Endocrinol Metab. 2012 Mar;97(3):819-27. doi: 10.1210/jc.2011-2486. Epub 2011 Dec 14.

19.

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.

Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T.

J Am Coll Cardiol. 2010 Mar 9;55(10):976-82. doi: 10.1016/j.jacc.2009.09.062.

20.

Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE.

JAMA. 2007 Feb 7;297(5):499-508.

PMID:
17284700

Supplemental Content

Support Center